Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/
US: Third follow-on biologics bill, Promoting Innovation and Access to Life-Saving Medicine Act in 111th Congress; draws industry ire (Patent Docs) (Law360)
Brazil, India, EU: Seizures on drug consignments (Spicy IP)
Brazil: Widestrike GM cotton approved in Brazil (IP tango)
Canada: Access to drugs: Canada’s one licence solution (Afro-IP)
China: How to protect traditional Chinese medicine? (IP Dragon)
EU: Negative term SPC duration: A business intelligence consultant’s perspective (The SPC Blog)
EU: Q: When is medical use no use? A: When it’s in a patent claim. (IPKat)
US: Third follow-on biologics bill, Promoting Innovation and Access to Life-Saving Medicine Act in 111th Congress; draws industry ire (Patent Docs) (Law360)
US: CAFC: Anticipation of genus by prior art species in long list: In re Gleave (Hal Wegner) (Patent Docs)
US: Life Technologies, General Electric settle patent suit over DNA amplification kits (Law360)
Concerta (Methylphenidate) – US: Delaware court rules Watson does not infringe patent related to generic version of Concerta and declares patent invalid (SmartBrief) (GenericsWeb)
Fosrenol (Lanthanum) – US: Shire files lawsuit against Natco Pharma for infringement of Fosrenol patents (GenericsWeb)
Gemzar (Gemcitabine) – UK: Expert witnesses – is there a better way?: Scinopharm Taiwan Ltd v Eli Lily & Co (PatLit)
Naglazyme (Galsulfase) – Brazil: Federal Court of the First Region orders government to supply unapproved drug Naglazyme (IP tango)
Plavix (Clopidogrel) – US: Bristol-Myers Squibb to pay $2.1 million to settle FTC claims it issues misleading statement about proposed Plavix patent deal with Apotex, violating court orders from earlier anti-trust cases (Law360)
Razadyne (Galantamine) – US: Johnson & Johnson units resolve patent infringement dispute with generic drug makers including Janssen over Razadyne (Law360)